Abstract
Chronic Pain syndromes and Major Depressive Disorder account for two of the most costly and prevalent illnesses worldwide and are frequently comorbid and treatment resistant. In this review, we examine the current role of ketamine, a potent NMDA (N-methl-D-aspartic acid) receptor blocker, in treating chronic pain and major depression. The role of the NMDA receptor and glutamatergic system are increasingly being studied in mood disorders, and are known components in pain processing, opioid induced analgesic tolerance, and hyperalgesia. We propose a hypothetic therapeutic role of ketamine involving the opioidergic pathway in these patients with treatment resistant chronic pain and major depressive disorder.
Keywords: Chronic pain, ketamine, major depressive disorder, neuropathic pain, nmda receptor antagonist, opioid tolerance, opioid resistance, analgesic, hyperalgesia, dysthymia, antidepressant, neurotransmitters, glutamate receptor, synaptic plasticity, coincidence detector, cholinergic receptors, kappa opioid receptors, psychomimetic, serotonin, anesthetic effect, cerebral vasodilation, hallucinations, nightmares, morphine, benzodiazepine, tachyarrhythmias, schizophrenia, allodynia, lidocaine, postherpetic neuralgia, xerostomia, Limb Pain, Fibromyalgia, Pluronic lecithin organogel, Stump/Phantom, Whiplash Pain, Placebo-controlled, Montgomery, –, Asberg Depression Rating Scale, lamotrigine, epidural, Opioidergic, Glutamatergic Dysfunction, naloxone
Current Drug Therapy
Title: Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis
Volume: 5 Issue: 4
Author(s): Christine Chang, David Bezov and Marco Pappagallo
Affiliation:
Keywords: Chronic pain, ketamine, major depressive disorder, neuropathic pain, nmda receptor antagonist, opioid tolerance, opioid resistance, analgesic, hyperalgesia, dysthymia, antidepressant, neurotransmitters, glutamate receptor, synaptic plasticity, coincidence detector, cholinergic receptors, kappa opioid receptors, psychomimetic, serotonin, anesthetic effect, cerebral vasodilation, hallucinations, nightmares, morphine, benzodiazepine, tachyarrhythmias, schizophrenia, allodynia, lidocaine, postherpetic neuralgia, xerostomia, Limb Pain, Fibromyalgia, Pluronic lecithin organogel, Stump/Phantom, Whiplash Pain, Placebo-controlled, Montgomery, –, Asberg Depression Rating Scale, lamotrigine, epidural, Opioidergic, Glutamatergic Dysfunction, naloxone
Abstract: Chronic Pain syndromes and Major Depressive Disorder account for two of the most costly and prevalent illnesses worldwide and are frequently comorbid and treatment resistant. In this review, we examine the current role of ketamine, a potent NMDA (N-methl-D-aspartic acid) receptor blocker, in treating chronic pain and major depression. The role of the NMDA receptor and glutamatergic system are increasingly being studied in mood disorders, and are known components in pain processing, opioid induced analgesic tolerance, and hyperalgesia. We propose a hypothetic therapeutic role of ketamine involving the opioidergic pathway in these patients with treatment resistant chronic pain and major depressive disorder.
Export Options
About this article
Cite this article as:
Chang Christine, Bezov David and Pappagallo Marco, Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis, Current Drug Therapy 2010; 5 (4) . https://dx.doi.org/10.2174/157488510792927447
DOI https://dx.doi.org/10.2174/157488510792927447 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry Multifunctional Therapeutic Delivery Strategies for Effective Neuro-Regeneration Following Traumatic Spinal Cord Injury
Current Pharmaceutical Design Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Liver Growth Factor as a Tissue Regenerating Factor in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor-γ Ligand in Chronic Cerebral Hypoperfusion
Current Neurovascular Research Optogenetics of the Spinal Cord: Use of Channelrhodopsin Proteins for Interrogation of Spinal Cord Circuits
Current Protein & Peptide Science Neurorestorative Role of Stem Cells in Alzheimer’s Disease: Astrocyte Involvement
Current Alzheimer Research Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology Cell Death in Mammalian Development
Current Pharmaceutical Design Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Commentary: Multifactoriality of Amytrophic Lateral Sclerosis: Linking Unfolded Proteins to Oxidative Stress in Microglia
CNS & Neurological Disorders - Drug Targets